LAVA Therapeutics NV (LAVA Therapeutics NV) Equity-to-Asset : 0.50 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LAVA Therapeutics NV Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. LAVA Therapeutics NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $51.18 Mil. LAVA Therapeutics NV's Total Assets for the quarter that ended in Dec. 2023 was $101.71 Mil. Therefore, LAVA Therapeutics NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.50.

The historical rank and industry rank for LAVA Therapeutics NV's Equity-to-Asset or its related term are showing as below:

LVTX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37 Med: 0.6 Max: 0.85
Current: 0.5

During the past 5 years, the highest Equity to Asset Ratio of LAVA Therapeutics NV was 0.85. The lowest was 0.37. And the median was 0.60.

LVTX's Equity-to-Asset is ranked worse than
64.18% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs LVTX: 0.50

LAVA Therapeutics NV Equity-to-Asset Historical Data

The historical data trend for LAVA Therapeutics NV's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LAVA Therapeutics NV Equity-to-Asset Chart

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.66

0.37

0.85

0.60

0.50

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial												0.60	0.56	0.52	0.49	0.50

Competitive Comparison of LAVA Therapeutics NV's Equity-to-Asset

For the Biotechnology subindustry, LAVA Therapeutics NV's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's Equity-to-Asset falls into.

LAVA Therapeutics NV Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

LAVA Therapeutics NV's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	51.178	/	101.71
	=	0.50

LAVA Therapeutics NV's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	51.178	/	101.71
	=	0.50

LAVA Therapeutics NV (NAS:LVTX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

LAVA Therapeutics NV Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.